Whereas, the amount of DCs (CD11c+ MHC IIhigh F4/80−) within the tumor decreased (Fig. 7C), we found that the frequency of the cross presenting XCR1+ subtype of DCs within the DC population was obviously higher in tumors treated with Ad5/11-αCD3TAT-Trimer. This evidence concerns the gene ITGAX and neoplasm.